Encysive to consider alternatives

By Lisa Kerner

Charlotte, N.C., July 17 - Encysive Pharmaceuticals Inc. will evaluate strategic alternatives to maximize shareholder value with the assistance of Morgan Stanley, according to a company news release.

The Houston biopharmaceutical company said it doesn't expect to publicly disclose further information until a definitive transaction is entered into or the process is completed. In addition, there can be no assurances that any particular alternative will be pursued or that any transaction will occur.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.